144 related articles for article (PubMed ID: 27546834)
1. Pharmacophore Model To Discover OX1 and OX2 Orexin Receptor Ligands.
Turku A; Borrel A; Leino TO; Karhu L; Kukkonen JP; Xhaard H
J Med Chem; 2016 Sep; 59(18):8263-75. PubMed ID: 27546834
[TBL] [Abstract][Full Text] [Related]
2. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.
Perrey DA; German NA; Decker AM; Thorn D; Li JX; Gilmour BP; Thomas BF; Harris DL; Runyon SP; Zhang Y
ACS Chem Neurosci; 2015 Apr; 6(4):599-614. PubMed ID: 25643283
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach.
Heidmann B; Gatfield J; Roch C; Treiber A; Tortoioli S; Brotschi C; Williams JT; Bolli MH; Abele S; Sifferlen T; Jenck F; Boss C
ChemMedChem; 2016 Oct; 11(19):2132-2146. PubMed ID: 27390287
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878.
Maehara S; Yuge N; Higashi C; Ota T; Furukawa J; Takeuchi T
Neuropsychopharmacol Rep; 2020 Jun; 40(2):182-189. PubMed ID: 32337858
[TBL] [Abstract][Full Text] [Related]
5. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
Yin J; Babaoglu K; Brautigam CA; Clark L; Shao Z; Scheuermann TH; Harrell CM; Gotter AL; Roecker AJ; Winrow CJ; Renger JJ; Coleman PJ; Rosenbaum DM
Nat Struct Mol Biol; 2016 Apr; 23(4):293-9. PubMed ID: 26950369
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
Rappas M; Ali AAE; Bennett KA; Brown JD; Bucknell SJ; Congreve M; Cooke RM; Cseke G; de Graaf C; Doré AS; Errey JC; Jazayeri A; Marshall FH; Mason JS; Mould R; Patel JC; Tehan BG; Weir M; Christopher JA
J Med Chem; 2020 Feb; 63(4):1528-1543. PubMed ID: 31860301
[TBL] [Abstract][Full Text] [Related]
7. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study.
Karhu L; Magarkar A; Bunker A; Xhaard H
J Phys Chem B; 2019 Mar; 123(12):2609-2622. PubMed ID: 30786708
[TBL] [Abstract][Full Text] [Related]
8. Azulene-based compounds for targeting orexin receptors.
Leino TO; Turku A; Yli-Kauhaluoma J; Kukkonen JP; Xhaard H; Wallén EAA
Eur J Med Chem; 2018 Sep; 157():88-100. PubMed ID: 30077889
[TBL] [Abstract][Full Text] [Related]
9. OX
Yamaguchi M; Ishikawa M; Aono Y; Saigusa T
Neuropsychopharmacol Rep; 2020 Mar; 40(1):30-38. PubMed ID: 31845549
[TBL] [Abstract][Full Text] [Related]
10. OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells.
Kukkonen JP
Cell Signal; 2016 Feb; 28(2):51-60. PubMed ID: 26582739
[TBL] [Abstract][Full Text] [Related]
11. Orexin Receptor Antagonists: Historical Perspectives and Future Opportunities.
Andrews SP; Aves SJ; Christopher JA; Nonoo R
Curr Top Med Chem; 2016; 16(29):3438-3469. PubMed ID: 26416477
[TBL] [Abstract][Full Text] [Related]
12. Structure-Activity Relationships of 1-Benzoylazulenes at the OX
Turku A; Leino TO; Karhu L; Yli-Kauhaluoma J; Kukkonen JP; Wallén EAA; Xhaard H
ChemMedChem; 2019 May; 14(9):965-981. PubMed ID: 30892823
[TBL] [Abstract][Full Text] [Related]
13. Orexins/hypocretins modulate the activity of NPY-positive and -negative neurons in the rat intergeniculate leaflet via OX1 and OX2 receptors.
Palus K; Chrobok L; Lewandowski MH
Neuroscience; 2015 Aug; 300():370-80. PubMed ID: 26022361
[TBL] [Abstract][Full Text] [Related]
14. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
[TBL] [Abstract][Full Text] [Related]
15. Orexin Directly Enhances the Excitability of Globus Pallidus Internus Neurons in Rat by Co-activating OX1 and OX2 Receptors.
Gao HR; Zhuang QX; Zhang YX; Chen ZP; Li B; Zhang XY; Zhong YT; Wang JJ; Zhu JN
Neurosci Bull; 2017 Aug; 33(4):365-372. PubMed ID: 28389870
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Discovery of Novel Ligands for the Orexin 2 Receptor.
Gunera J; Baker JG; van Hilten N; Rosenbaum DM; Kolb P
J Med Chem; 2020 Oct; 63(19):11045-11053. PubMed ID: 32977721
[TBL] [Abstract][Full Text] [Related]
17. Nucleus incertus Orexin2 receptors mediate alcohol seeking in rats.
Kastman HE; Blasiak A; Walker L; Siwiec M; Krstew EV; Gundlach AL; Lawrence AJ
Neuropharmacology; 2016 Nov; 110(Pt A):82-91. PubMed ID: 27395787
[TBL] [Abstract][Full Text] [Related]
18. Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands.
Mould R; Brown J; Marshall FH; Langmead CJ
Br J Pharmacol; 2014 Jan; 171(2):351-63. PubMed ID: 23692283
[TBL] [Abstract][Full Text] [Related]
19. The Subthalamic Neurons are Activated by Both Orexin-A and Orexin-B.
Sheng Q; Xue Y; Wang Y; Chen AQ; Liu C; Liu YH; Chu HY; Chen L
Neuroscience; 2018 Jan; 369():97-108. PubMed ID: 29138106
[TBL] [Abstract][Full Text] [Related]
20. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.
Yoshida Y; Naoe Y; Terauchi T; Ozaki F; Doko T; Takemura A; Tanaka T; Sorimachi K; Beuckmann CT; Suzuki M; Ueno T; Ozaki S; Yonaga M
J Med Chem; 2015 Jun; 58(11):4648-64. PubMed ID: 25953512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
